Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Takeda Pharmaceutical Co ( (JP:4502) ) has shared an announcement.
Takeda Pharmaceutical Co. has announced its decision to acquire up to 28.5 million of its own common stock shares, valued at up to JPY 100 billion. This strategic move, scheduled between February and May 2025, aims to enhance capital efficiency and improve returns for shareholders, potentially strengthening Takeda’s market position and benefiting its stakeholders.
More about Takeda Pharmaceutical Co
Takeda Pharmaceutical Company Limited is a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan. The company is focused on discovering and delivering life-transforming treatments in areas such as gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. Takeda aims to improve patient experiences and advance treatment options through its dynamic pipeline, operating in approximately 80 countries.
YTD Price Performance: -2.61%
Average Trading Volume: 17,247
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $42.73B
For an in-depth examination of 4502 stock, go to TipRanks’ Stock Analysis page.
